265 related articles for article (PubMed ID: 22431865)
21. [Possible application of pharmacogenomics to warfarin therapy].
Murata M
Rinsho Byori; 2011 Jun; 59(6):594-7. PubMed ID: 21815482
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetic-based dosing of warfarin.
Med Lett Drugs Ther; 2008 May; 50(1286):39-40. PubMed ID: 18487958
[No Abstract] [Full Text] [Related]
23. Role of warfarin pharmacogenetic testing in clinical practice.
Tan GM; Wu E; Lam YY; Yan BP
Pharmacogenomics; 2010 Mar; 11(3):439-48. PubMed ID: 20402581
[TBL] [Abstract][Full Text] [Related]
24. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting.
Sasaki T; Tabuchi H; Higuchi S; Ieiri I
Pharmacogenomics; 2009 Aug; 10(8):1257-66. PubMed ID: 19663670
[TBL] [Abstract][Full Text] [Related]
25. Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population.
Pavani A; Naushad SM; Mishra RC; Malempati AR; Pinjala R; Kumar TR; Kutala VK
Pharmacogenomics; 2012 Jun; 13(8):869-78. PubMed ID: 22676192
[TBL] [Abstract][Full Text] [Related]
26. Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.
Gao L; He L; Luo J; Xu B; Yang J; Zhang YX; Yang T; Li K; Tian JW; Wang HJ; Zhao YS; Lu CY; Zhang WZ; Yin T
Chin Med J (Engl); 2011 Sep; 124(17):2767-70. PubMed ID: 22040439
[TBL] [Abstract][Full Text] [Related]
27. Optimization of warfarin dose by population-specific pharmacogenomic algorithm.
Pavani A; Naushad SM; Rupasree Y; Kumar TR; Malempati AR; Pinjala RK; Mishra RC; Kutala VK
Pharmacogenomics J; 2012 Aug; 12(4):306-11. PubMed ID: 21358752
[TBL] [Abstract][Full Text] [Related]
28. The Creating an Optimal Warfarin Nomogram (CROWN) Study.
Perlstein TS; Goldhaber SZ; Nelson K; Joshi V; Morgan TV; Lesko LJ; Lee JY; Gobburu J; Schoenfeld D; Kucherlapati R; Freeman MW; Creager MA
Thromb Haemost; 2012 Jan; 107(1):59-68. PubMed ID: 22116191
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenetic guided versus standard warfarin dosing for routine clinical care with its pharmacoeconomic impact: a randomized controlled clinical trial.
Anand A; Hegde NC; Chhabra P; Purohit J; Kumar R; Gupta A; Lad DP; Mohindra R; Mehrotra S; Vijayvergiya R; Kumar B; Sharma V; Malhotra P; Ahluwalia J; Das R; Patil AN; Shafiq N; Malhotra S
Ann Hematol; 2024 Jun; 103(6):2133-2144. PubMed ID: 38634917
[TBL] [Abstract][Full Text] [Related]
30. Estimation of the warfarin dose with clinical and pharmacogenetic data.
; Klein TE; Altman RB; Eriksson N; Gage BF; Kimmel SE; Lee MT; Limdi NA; Page D; Roden DM; Wagner MJ; Caldwell MD; Johnson JA
N Engl J Med; 2009 Feb; 360(8):753-64. PubMed ID: 19228618
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients.
Takeuchi F; Kashida M; Okazaki O; Tanaka Y; Fukuda S; Kashima T; Hosaka S; Hiroe M; Kimura S; Kato N
Circ J; 2010 May; 74(5):977-82. PubMed ID: 20339191
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.
Patrick AR; Avorn J; Choudhry NK
Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):429-36. PubMed ID: 20031873
[TBL] [Abstract][Full Text] [Related]
34. Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients.
Yoshizawa M; Hayashi H; Tashiro Y; Sakawa S; Moriwaki H; Akimoto T; Doi O; Kimura M; Kawarasaki Y; Inoue K; Itoh K
Thromb Res; 2009 Jun; 124(2):161-6. PubMed ID: 19135231
[TBL] [Abstract][Full Text] [Related]
35. Algorithms using clinical and genetic data (CYP2C9, VKORC1) are relevant to predict warfarin dose in patients with different INR targets.
Le Cam-Duchez V; Frétigny M; Cailleux N; Gandelin C; Lévesque H; Borg JY
Thromb Res; 2010 Sep; 126(3):e235-7. PubMed ID: 20569971
[No Abstract] [Full Text] [Related]
36. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy.
Horne BD; Lenzini PA; Wadelius M; Jorgensen AL; Kimmel SE; Ridker PM; Eriksson N; Anderson JL; Pirmohamed M; Limdi NA; Pendleton RC; McMillin GA; Burmester JK; Kurnik D; Stein CM; Caldwell MD; Eby CS; Rane A; Lindh JD; Shin JG; Kim HS; Angchaisuksiri P; Glynn RJ; Kronquist KE; Carlquist JF; Grice GR; Barrack RL; Li J; Gage BF
Thromb Haemost; 2012 Feb; 107(2):232-40. PubMed ID: 22186998
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.
Perini JA; Struchiner CJ; Silva-Assunção E; Santana IS; Rangel F; Ojopi EB; Dias-Neto E; Suarez-Kurtz G
Clin Pharmacol Ther; 2008 Dec; 84(6):722-8. PubMed ID: 18754001
[TBL] [Abstract][Full Text] [Related]
38. A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation.
Pengo V; Zambon CF; Fogar P; Padoan A; Nante G; Pelloso M; Moz S; Frigo AC; Groppa F; Bozzato D; Tiso E; Gnatta E; Denas G; Padayattil Jose S; Padrini R; Basso D; Plebani M
PLoS One; 2015; 10(12):e0145318. PubMed ID: 26710337
[TBL] [Abstract][Full Text] [Related]
39. Warfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithms.
Hamberg AK; Friberg LE; Hanséus K; Ekman-Joelsson BM; Sunnegårdh J; Jonzon A; Lundell B; Jonsson EN; Wadelius M
Eur J Clin Pharmacol; 2013 Jun; 69(6):1275-83. PubMed ID: 23307232
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetics of coumarinic oral anticoagulants.
Manolopoulos VG; Ragia G; Tavridou A
Pharmacogenomics; 2010 Apr; 11(4):493-6. PubMed ID: 20350128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
